Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sonnet Biotherapeutics stock

Learn how to easily invest in Sonnet Biotherapeutics stock.

Sonnet Biotherapeutics is a biotechnology business based in the US. Sonnet Biotherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet Biotherapeutics employs 12 staff and has a trailing 12-month revenue of around $349,943.

How to buy Sonnet Biotherapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – SONN. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Sonnet Biotherapeutics stock price (NASDAQ: SONN)

Use our graph to track the performance of SONN stocks over time.

Sonnet Biotherapeutics shares at a glance

Information last updated 2023-01-26.
Latest market close$1.16
52-week range$0.91 - $9.37
50-day moving average $1.13
200-day moving average $2.68
Wall St. target price$18.90
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.60

Buy Sonnet Biotherapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Sonnet Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sonnet Biotherapeutics price performance over time

Historical closes compared with the close of $1.16 from 2023-01-27

1 week (2023-01-24) -0.85%
1 month (2022-12-30) 0.87%
3 months (2022-10-31) -39.90%
6 months (2022-07-29) 329.63%
1 year (2022-01-31) 254.74%
2 years (2021-01-29) -55.89%
3 years (2020-01-31) 81.19%
5 years (2018-01-30) 3.8699

Sonnet Biotherapeutics financials

Revenue TTM $349,943
Gross profit TTM $-21,094,076
Return on assets TTM -106.5%
Return on equity TTM -301.42%
Profit margin 0%
Book value $-0.46
Market capitalisation $9.1 million

TTM: trailing 12 months

Sonnet Biotherapeutics share dividends

We're not expecting Sonnet Biotherapeutics to pay a dividend over the next 12 months.

Have Sonnet Biotherapeutics's shares ever split?

Sonnet Biotherapeutics's shares were split on a 1:14 basis on 18 September 2022. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet Biotherapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Sonnet Biotherapeutics shares which in turn could have impacted Sonnet Biotherapeutics's share price.

Sonnet Biotherapeutics share price volatility

Over the last 12 months, Sonnet Biotherapeutics's shares have ranged in value from as little as $0.91 up to $9.3716. A popular way to gauge a stock's volatility is its "beta".

SONN.US volatility(beta: 0.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonnet Biotherapeutics's is 0.5851. This would suggest that Sonnet Biotherapeutics's shares are less volatile than average (for this exchange).

Sonnet Biotherapeutics overview

Sonnet BioTherapeutics Holdings, Inc. , a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6.

Frequently asked questions

What percentage of Sonnet Biotherapeutics is owned by insiders or institutions?
Currently 2.127% of Sonnet Biotherapeutics shares are held by insiders and 3.249% by institutions.
How many people work for Sonnet Biotherapeutics?
Latest data suggests 12 work at Sonnet Biotherapeutics.
When does the fiscal year end for Sonnet Biotherapeutics?
Sonnet Biotherapeutics's fiscal year ends in December.
Where is Sonnet Biotherapeutics based?
Sonnet Biotherapeutics's address is: 100 Overlook Center, Princeton, NJ, United States, 08540
What is Sonnet Biotherapeutics's ISIN number?
Sonnet Biotherapeutics's international securities identification number is: US83548R1059
What is Sonnet Biotherapeutics's CUSIP number?
Sonnet Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 15930P503

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site